James F Callahan
Overview
Explore the profile of James F Callahan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1473
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wilson A, Kerns J, Callahan J, Moody C
J Med Chem
. 2013 Jul;
56(19):7463-76.
PMID: 23837912
The Nrf2-Keap1 system plays a major role in cellular defense against oxidative stress. Upon exposure to electrophiles, the cysteine-rich protein Keap1 is covalently modified, and it is this modification of...
12.
Podolin P, Bolognese B, Foley J, Long 3rd E, Peck B, Umbrecht S, et al.
Prostaglandins Other Lipid Mediat
. 2013 Feb;
104-105:25-31.
PMID: 23434473
Soluble epoxide hydrolase (sEH, EPHX2) metabolizes eicosanoid epoxides, including epoxyeicosatrienoic acids (EETs) to the corresponding dihydroxyeicosatrienoic acids (DHETs), and leukotoxin (LTX) to leukotoxin diol (LTX diol). EETs, endothelium-derived hyperpolarizing factors,...
13.
Zhu P, Peck B, Licea-Perez H, Callahan J, Booth-Genthe C
J Chromatogr B Analyt Technol Biomed Life Sci
. 2011 Jul;
879(25):2487-93.
PMID: 21798825
Substrates and products of soluble epoxide hydrolase (sEH) such as 14,15-epoxyeicosatrienoic acid (14,15-EET), 14,15-dihydroxyeicosatrienoic acid (14,15-DHET), leukotoxin, and leukotoxin diol are potential biomarkers for assessing sEH activity in clinical trial...
14.
Tontchev G, Housel T, Callahan J, Kunz K, Miller M, Blondell R
Subst Abus
. 2011 May;
32(2):84-92.
PMID: 21534129
In the United States accredited residency programs in addiction exist only for psychiatrists specializing in addiction psychiatry (ADP); nonpsychiatrists seeking training in addiction medicine (ADM) can train in nonaccredited "fellowships,"...
15.
Marquis R, Lago A, Callahan J, Rahman A, Dong X, Stroup G, et al.
J Med Chem
. 2009 Oct;
52(21):6599-605.
PMID: 19821575
When administered as a single agent to rats, the previously reported calcium receptor antagonist 3 elicited a sustained elevation of plasma PTH resulting in no increase in overall bone mineral...
16.
Kumar S, Matheny C, Hoffman S, Marquis R, Schultz M, Liang X, et al.
Bone
. 2009 Sep;
46(2):534-42.
PMID: 19786130
Daily subcutaneous administration of exogenous parathyroid hormone (PTH) promotes bone formation in patients with osteoporosis. Here we describe two novel, short-acting calcium-sensing receptor antagonists (SB-423562 and its orally bioavailable precursor,...
17.
Bamborough P, Callahan J, Christopher J, Kerns J, Liddle J, Miller D, et al.
Curr Top Med Chem
. 2009 Aug;
9(7):623-39.
PMID: 19689370
The IkappaB kinases (IKKs) are essential components of the signaling pathway by which the NF-kappaB p50/RelA transcription factor is activated in response to pro-inflammatory stimuli such as lipopolysaccharide (LPS) and...
18.
Marquis R, Lago A, Callahan J, Trout R, Gowen M, DelMar E, et al.
J Med Chem
. 2009 Jun;
52(13):3982-93.
PMID: 19492813
Functional screening of the former SmithKline Beecham compound collection against the human calcium receptor (CaR) resulted in the identification of the amino alcohol-based hit 2 (IC(50) = 11 microM). Structure-activity...
19.
Podolin P, Callahan J, Bolognese B, Li Y, Carlson K, Davis T, et al.
J Pharmacol Exp Ther
. 2004 Aug;
312(1):373-81.
PMID: 15316093
Demonstration that IkappaB kinase 2 (IKK-2) plays a pivotal role in the nuclear factor-kappaB-regulated production of proinflammatory molecules by stimuli such as tumor necrosis factor (TNF)-alpha and interleukin (IL)-1 suggests...
20.
Inman G, Nicolas F, Callahan J, Harling J, Gaster L, Reith A, et al.
Mol Pharmacol
. 2002 Jun;
62(1):65-74.
PMID: 12065756
Small molecule inhibitors have proven extremely useful for investigating signal transduction pathways and have the potential for development into therapeutics for inhibiting signal transduction pathways whose activities contribute to human...